Holen Sie sich die Stockscreener-App
2.17
3.98%
-0.09
Handel nachbörslich:
2.15
-0.02
-0.92%
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
Century Advances Diabetes Cell Therapy Toward Human Trials - MyChesCo
IPSC Stock Price, Quote & Chart | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics Q1 2026 Earnings: EPS Surpasses Estimates as Pipeline Progress ContinuesRising Community Picks - Newser
IPSC (NASDAQ: IPSC) resale supplement substitutes Point72 with SILV Fund - Stock Titan
Century Therapeutics (IPSC) CEO has 31,172 shares withheld to cover RSU tax obligations - Stock Titan
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - MSN
Century Therapeutics (IPSC) Stock: Slides -1.68%, Support at $2.22 2026-05-15Professional Trade Ideas - newser.com
Point72 group reports 5.96M-share stake in Century Therapeutics (IPSC) - Stock Titan
RTW Investments and R. Wong report 7.1% stake in Century Therapeutics (IPSC) - Stock Titan
Century Therapeutics 1Q Research and Development Expenses $17.1M >IPSC - Moomoo
Versant Venture Management, LLC's Century Therapeutics Inc(IPSC) Holding History - GuruFocus
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Investing News Network
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Century Therapeutics (IPSC) Gains +1.80% — Support Holds at $2.20 2026-05-14Long Setup - newser.com
Century Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Century Therapeutics Reports First Quarter Financial Results and Business Updates - Investing News Network
Century Therapeutics Reports Q1 2026 Financial Results, Advances iPSC-Derived Diabetes and Cancer Therapies, Cash Runway to 2029 - Minichart
Century Therapeutics Q1 Earnings Beat Expectations - Intellectia AI
Century Therapeutics reports Q1 net loss $21.6M, cash runway into Q1 2029 - TradingView
Century Therapeutics 1Q 2026: Revenue ($22.26M), Net income ($21.65M), EPS ($0.11) — 10-Q Summary - TradingView
Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend - TradingView
Century Therapeutics (NASDAQ: IPSC) swings to Q1 2026 loss as prior collaboration revenue rolls off - Stock Titan
Century Therapeutics (IPSC) swings to Q1 2026 loss as one-time collaboration revenue ends - Stock Titan
TradingKey - TradingKey
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock By Investing.com - Investing.com South Africa
Douglas Carr, SVP at Century Therapeutics, sells $618 in stock - Investing.com India
SVP at Century Therapeutics (IPSC) sells shares to cover taxes - Stock Titan
How will Century Therapeutics (IPSC) earnings compare to expectations | Q4 2025: Better Than ExpectedROE - newser.com
Wall Street Zen Upgrades Century Therapeutics (NASDAQ:IPSC) to Hold - MarketBeat
H.C. Wainwright Increases Century Therapeutics Price Target to Five Dollars - HarianBasis.co
Century Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC) - Insider Monkey
Century Therapeutics Selected for Oral Presentation of CNTY?813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Century Therapeutics to present diabetes therapy data at ADA - Investing.com
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions - The Manila Times
Century Therapeutics to present diabetes therapy data at ADA By Investing.com - Investing.com Canada
Century Therapeutics (NASDAQ: IPSC) sets 2026 virtual meeting and share authorization vote - Stock Titan
Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
iPSC-Derived NK Cells Pipeline Set to Transform Cancer Immunotherapy Landscape with 15+ Emerging Therapies and Strong Innovation Momentum from Century Therapeutics, Fate Therapeutics | DelveInsight - Barchart.com
What is HC Wainwright's Estimate for IPSC Q1 Earnings? - MarketBeat
IPSC Century Therapeutics Inc. posts narrower Q4 2025 loss than expected, shares gain 6.56 percent in daily trading.Margin of Safety - UBND thành phố Hải Phòng
Arrowhead Pharmaceuticals To Rally Over 44%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
IPSC Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
H.C. Wainwright raises Century Therapeutics price target on diabetes therapy potential - Investing.com Canada
Century Therapeutics (IPSC) Stock: Market Signals (Investor Concern) 2026-04-20Viral Momentum Trades - Newser
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 19.3% in March - MarketBeat
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):